Dermatology · Clinical trials
Vitiligo Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About vitiligo — and why its trials are hard
Vitiligo is a chronic autoimmune disorder in which melanocytes are destroyed, producing well-demarcated depigmented (milky-white) macules and patches on the skin. The most common form, nonsegmental vitiligo, is often symmetric and progressive, while segmental vitiligo follows a more localized, unilateral distribution. Although not physically painful, vitiligo carries a significant psychosocial burden and is associated with other autoimmune conditions such as thyroid disease. Its pathogenesis centers on a CD8+ T-cell attack on melanocytes driven by interferon-gamma signaling through the JAK-STAT pathway, which provided the rationale for JAK inhibition. For decades there were no FDA-approved therapies specifically indicated to restore pigment; management relied on off-label topical corticosteroids, calcineurin inhibitors, and phototherapy (notably narrowband UVB). This changed in July 2022 when ruxolitinib cream (Opzelura), a topical JAK1/JAK2 inhibitor, became the first FDA-approved repigmentation therapy for nonsegmental vitiligo, based on the pivotal TRuE-V program. Repigmentation is gradual, and facial areas typically respond best, with continued treatment often required.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Ruxolitinib cream (Opzelura) | 2022 | First FDA-approved repigmentation therapy for nonsegmental vitiligo (topical JAK1/JAK2 inhibitor) | TRuE-V1 and TRuE-V2 (Phase 3, NEJM 2022) | F-VASI75 (>=75% improvement in Facial Vitiligo Area Scoring Index) at week 24 | F-VASI75 achieved by ~29-30% with ruxolitinib cream vs ~8-13% with vehicle at week 24; responses increased further by week 52 |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in vitiligo development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Historically, no targeted repigmentation therapy — (unverified) | Prior to 2022, no drug had been FDA-approved specifically to repigment vitiligo; care relied on off-label topical steroids, calcineurin inhibitors, and phototherapy | The absence of validated endpoints and targeted mechanisms historically limited successful registrational programs; specific failed pivotal trials are not well documented (unverified) |
Choosing the right endpoint
Primary endpoints that matter in vitiligo trials
- F-VASI75 — At least 75% improvement in the Facial Vitiligo Area Scoring Index; primary endpoint of the TRuE-V trials given the cosmetic importance and responsiveness of facial skin
- T-VASI (Total Vitiligo Area Scoring Index) — Whole-body measure of depigmented surface area used as a secondary endpoint to assess overall repigmentation
- F-VASI50 / F-VASI90 — Lower and higher facial response thresholds capturing the range and depth of repigmentation over time
- Vitiligo Noticeability Scale (patient-reported) — Patient assessment of how noticeable residual vitiligo is, reflecting cosmetic and psychosocial benefit
How iNGENū runs vitiligo trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Vitiligo clinical trials — FAQs
Why was ruxolitinib cream considered a landmark approval?
How quickly does repigmentation occur?
Why do JAK inhibitors work in vitiligo?
Ready to discuss your vitiligo trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal